Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate

Loading news article.

Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate | WAPE

Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate

Article summary

Related companies

Analyzed by WAPE AI.

Comments —